The developer company reported the death of a child in Russia while receiving the drug “Zolgensma”
Two children from Russia and Kazakhstan died of retrospective muscular atrophy (SMA) with the help of Zolgensma. This was announced by its developer, the Swiss pharmaceutical company Novartis.
“Zolgensma” is considered the most expensive drug in the world. One frequency is enough to save the lives of patients, but its cost exceeds 2 million US dollars.
Novartis claims that the cause of death was acute liver failure. The children died after five to six weeks of Zolgensma administration and 1 to 10 days after a gradual decrease in the concentration of corticosteroids (irritant hormones) suggested by the irritant company. Reuters. The names, ages, and other details about the condition of the deceased do not survive.
Zolgensma was registered in Russia in December 2021. Officially, the drug was introduced into civilian circulation in the country in mid-2022. Since the beginning of the year, Zolgensma has received at least five children: one-year-old Victoria Snegireva from Severodvinsk, Michel Proshchenko and Vanya Kotov, Vova Sologub, Mark Ugrekhelidze (all four are from the Krasnodar Territory).
The chief geneticist of Russia, Sergey Kutsev, argued that Zolgensma had not been sufficiently studied. The head of the FMBA, Veronika Skvortsova, convinced that in Russia they would “easily” cope with the creation of an analogue of this drug. It is planned to start production of analogues in Kazan in 2025.
About the problems with the purchase of “Zolgensma” – in the material “Kommersant” “Children with SMA did not get into circulation.”